Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Central role of RET in thyroid cancer.

Literature DB >> 24296167

Central role of RET in thyroid cancer.

Abstract

RET (rearranged during transfection) is a receptor tyrosine kinase involved in the development of neural crest derived cell lineages, kidney, and male germ cells. Different human cancers, including papillary and medullary thyroid carcinomas, lung adenocarcinomas, and myeloproliferative disorders display gain-of-function mutations in RET. Accordingly, RET protein has become a promising molecular target for cancer treatment.

Entities: Disease Gene Species

Mesh：

Substances：

Year: 2013 PMID： 24296167 PMCID： PMC3839608 DOI： 10.1101/cshperspect.a009233

Source DB: PubMed Journal: Cold Spring Harb Perspect Biol ISSN： 1943-0264 Impact factor: 10.005

130 in total

1. Mast cells have a protumorigenic role in human thyroid cancer.

Authors: R M Melillo; V Guarino; E Avilla; M R Galdiero; F Liotti; N Prevete; F W Rossi; F Basolo; C Ugolini; A de Paulis; M Santoro; G Marone
Journal: Oncogene Date: 2010-08-23 Impact factor: 9.867

2. Structure and chemical inhibition of the RET tyrosine kinase domain.

Authors: Phillip P Knowles; Judith Murray-Rust; Svend Kjaer; Rizaldy P Scott; Sarah Hanrahan; Massimo Santoro; Carlos F Ibáñez; Neil Q McDonald
Journal: J Biol Chem Date: 2006-08-23 Impact factor: 5.157

3. Heterogeneity in the distribution of RET/PTC rearrangements within individual post-Chernobyl papillary thyroid carcinomas.

Authors: Kristian Unger; Horst Zitzelsberger; Giuliana Salvatore; Massimo Santoro; Tatjana Bogdanova; Herbert Braselmann; Peter Kastner; Lyudmilla Zurnadzhy; Nikolay Tronko; Peter Hutzler; Gerry Thomas
Journal: J Clin Endocrinol Metab Date: 2004-09 Impact factor: 5.958

4. A new germline point mutation in Ret exon 8 (cys515ser) in a family with medullary thyroid carcinoma.

Authors: Francesca Fazioli; Gina Piccinini; Gloria Appolloni; Roberta Bacchiocchi; Gioia Palmonella; Rina Recchioni; Elisa Pierpaoli; Francesca Silvetti; Marina Scarpelli; Matteo Bruglia; Rosa Marina Melillo; Massimo Santoro; Marco Boscaro; Augusto Taccaliti
Journal: Thyroid Date: 2008-07 Impact factor: 6.568

5. Grb2 binding to the different isoforms of Ret tyrosine kinase.

Authors: L Alberti; M G Borrello; S Ghizzoni; F Torriti; M G Rizzetti; M A Pierotti
Journal: Oncogene Date: 1998-09-03 Impact factor: 9.867

6. Somatic mutations of the ret protooncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence.

Authors: C Romei; R Elisei; A Pinchera; I Ceccherini; E Molinaro; F Mancusi; E Martino; G Romeo; F Pacini
Journal: J Clin Endocrinol Metab Date: 1996-04 Impact factor: 5.958

7. RET/PTC rearrangements preferentially occurred in papillary thyroid cancer among atomic bomb survivors exposed to high radiation dose.

Authors: Kiyohiro Hamatani; Hidetaka Eguchi; Reiko Ito; Mayumi Mukai; Keiko Takahashi; Masataka Taga; Kazue Imai; John Cologne; Midori Soda; Koji Arihiro; Megumu Fujihara; Kuniko Abe; Tomayoshi Hayashi; Masahiro Nakashima; Ichiro Sekine; Wataru Yasui; Yuzo Hayashi; Kei Nakachi
Journal: Cancer Res Date: 2008-09-01 Impact factor: 12.701

Review 8. Chromosome fragile sites.

Authors: Sandra G Durkin; Thomas W Glover
Journal: Annu Rev Genet Date: 2007 Impact factor: 16.830

9. A novel de novo germ-line V292M mutation in the extracellular region of RET in a patient with phaeochromocytoma and medullary thyroid carcinoma: functional characterization.

Authors: Maria D Castellone; Antonella Verrienti; Deva Magendra Rao; Marialuisa Sponziello; Dora Fabbro; Magesh Muthu; Cosimo Durante; Marianna Maranghi; Giuseppe Damante; Stefano Pizzolitto; Giuseppe Costante; Diego Russo; Massimo Santoro; Sebastiano Filetti
Journal: Clin Endocrinol (Oxf) Date: 2010-10 Impact factor: 3.478

10. Identification of tyrosine 806 as a molecular determinant of RET kinase sensitivity to ZD6474.

Authors: Francesca Carlomagno; Teresa Guida; Suresh Anaganti; Livia Provitera; Svend Kjaer; Neil Q McDonald; Anderson J Ryan; Massimo Santoro
Journal: Endocr Relat Cancer Date: 2008-11-24 Impact factor: 5.678

33 in total

Review 1. Evolution of Our Understanding of the Hyperparathyroid Syndromes: A Historical Perspective.

Authors: Stephen J Marx; David Goltzman
Journal: J Bone Miner Res Date: 2018-12-10 Impact factor: 6.741

Review 2. The molecular basis for RET tyrosine-kinase inhibitors in thyroid cancer.

Authors: Valentina De Falco; Francesca Carlomagno; Hong-Yu Li; Massimo Santoro
Journal: Best Pract Res Clin Endocrinol Metab Date: 2017-05-10 Impact factor: 4.690

Review 3. Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes.

Authors: Alexander Drilon; Zishuo I Hu; Gillianne G Y Lai; Daniel S W Tan
Journal: Nat Rev Clin Oncol Date: 2017-11-14 Impact factor: 66.675

4. The RET E616Q Variant is a Gain of Function Mutation Present in a Family with Features of Multiple Endocrine Neoplasia 2A.

Authors: William Grey; Rosaline Hulse; Anna Yakovleva; Dilyana Genkova; Benjamin Whitelaw; Ellen Solomon; Salvador J Diaz-Cano; Louise Izatt
Journal: Endocr Pathol Date: 2017-03 Impact factor: 3.943

5. Oncogene-induced senescence and its evasion in a mouse model of thyroid neoplasia.

Authors: Roberto Bellelli; Donata Vitagliano; Giorgia Federico; Pina Marotta; Anna Tamburrino; Paolo Salerno; Orlando Paciello; Serenella Papparella; Jeffrey A Knauf; James A Fagin; Samuel Refetoff; Giancarlo Troncone; Massimo Santoro
Journal: Mol Cell Endocrinol Date: 2017-06-23 Impact factor: 4.102